Kura Oncology, Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined cancers. The filing covers the three and six months ended June 30, 2023. The pipeline included ziftomenib and tipifarnib in clinical development, KO-2806 preparing for first-in-human testing, and additional discovery-stage programs. The company had no approved products and no product revenue.
Financial condition and key metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Research and development expense | $28.2 million, versus $24.3 million | $53.4 million, versus $45.2 million |
| General and administrative expense | $11.8 million, versus $11.1 million | $23.2 million, versus $22.9 million |
| Total operating expenses | $40.0 million, versus $35.3 million | $76.6 million, versus $68.1 million |
| Net loss | $37.2 million, or $0.53 per share | $71.2 million, or $1.03 per share |
| Other income, net | $2.8 million, versus $0.6 million | $5.3 million, versus $0.9 million |
| Net cash used in operating activities | Not separately provided | $61.5 million, versus $62.5 million |
At June 30, 2023, cash and cash equivalents were $49.1 million, short-term investments were $427.9 million, and total cash, cash equivalents and short-term investments were approximately $477.0 million. Total assets were $494.7 million and stockholders’ equity was $459.7 million.
Long-term debt, net, was $9.2 million. The company had borrowed $10.0 million under a term loan facility providing for up to $125.0 million in total commitments. The loan matures in November 2027, bears interest at a variable rate subject to an 8.65% floor, and is secured by substantially all assets other than intellectual property.
Net cash provided by financing activities was $94.0 million, primarily from the June 2023 public offering. Net cash used in investing activities was $35.2 million, primarily reflecting purchases of marketable securities. Cash, cash equivalents and restricted cash decreased by $2.7 million during the first six months.
Material changes versus prior comparable periods
- First-half research and development expense increased $8.2 million, or approximately 18%, primarily due to higher ziftomenib, KO-2806, discovery-stage, personnel and share-based compensation costs. Tipifarnib-related costs declined following closure of its registration-directed trial.
- First-half net loss increased $4.0 million, while operating cash use improved by $1.0 million.
- Interest and other income increased substantially because of higher interest income on cash and investments; this partly offset higher operating expenses.
- The company completed a June public offering of 5,660,871 common shares and pre-funded warrants for 3,034,782 shares, generating approximately $93.6 million in net proceeds. The offering increased shares outstanding from 68.3 million at December 31, 2022 to 74.1 million at June 30, 2023, before considering warrant exercises.
- An employee retention credit of $2.8 million was recognized during the first half as a reduction of personnel costs and was included in prepaid expenses and other current assets. The company expected to receive the cash payment during the second half of 2023.
Guidance, outlook, commentary and risks
- Management stated that existing cash, cash equivalents and short-term investments were expected to fund operating expenses to mid-2026 based on current plans. The company expects to require substantial additional financing thereafter, and no assurance was provided that financing will be available on acceptable terms.
- Ziftomenib Phase 2 registration-directed enrollment in relapsed or refractory NPM1-mutant AML was continuing and was described as ahead of projections. The study is expected to enroll 85 patients at approximately 60 U.S. and European sites.
- The company expected preliminary data from the ziftomenib KOMET-007 combination study in the fourth quarter of 2023 or first quarter of 2024, expected to dose patients in KOMET-008 during the second half of 2023, and expected to begin post-transplant maintenance dosing in the first quarter of 2024.
- For tipifarnib, the company was evaluating the highest planned dose cohort in the KURRENT-HN combination study with Novartis-supplied alpelisib and intended to initiate a PIK3CA-mutant HNSCC dose expansion in mid-2024.
- For KO-2806, site activation had begun for the FIT-001 Phase 1 study, with first monotherapy dosing expected in the second half of 2023 and combination cohorts beginning in the second half of 2024.
- Key risks include failure or delay of clinical trials, safety events, regulatory non-approval, patient enrollment and companion-diagnostic challenges, dependence on contract research and manufacturing organizations, competition, intellectual-property limitations, potential future dilution, debt covenants and the need for additional capital.
- The company reported no material legal proceedings. Management concluded that disclosure controls and procedures were effective as of June 30, 2023, with no material changes to internal control over financial reporting.
Most important facts for investors to verify
- Whether ziftomenib’s Phase 2 registration-directed study remains on schedule and supports a viable regulatory filing strategy.
- Clinical efficacy, durability and safety data, including differentiation syndrome and other serious adverse events.
- Actual cash burn and whether the stated mid-2026 liquidity runway changes as combination trials and KO-2806 development expand.
- Terms, covenants, interest costs and future borrowing availability under the $125.0 million term loan facility.
- Potential dilution from the 3.0 million pre-funded warrants, outstanding options, restricted stock units, performance-based units and future equity financing.
- Progress and regulatory readiness of companion diagnostics and third-party manufacturing and clinical-trial arrangements.